Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis
作者： Sebastian Kufner , Salvatore Cassese , Marco Valeskini , Franz-Josef Neumann , Stefanie Schulz-Schüpke
DOI: 10.1016/J.JCIN.2015.01.031
关键词:
摘要: Abstract Objectives This study sought to investigate the long-term comparative efficacy and safety of paclitaxel-eluting balloon (PEB), stent (PES), or angioplasty (BA) for treatment drug-eluting restenosis. Background The optimal restenosis remains unknown. Although PEB has shown encouraging results, clinical poorly defined. Methods A total 402 patients with clinically significant in limus-eluting stents were randomly assigned receive (n = 137), PES 131), BA 134). For this analysis, versus compared. primary endpoints target lesion revascularization composite death myocardial infarction. Results At a median follow-up 3 years, risk was comparable (hazard ratio [HR]: 1.46, 95% confidence interval [CI]: 0.91 2.33; p = 0.11) lower (HR: 0.51, CI: 0.34 0.74; p Conclusions use as compared treat similar safety. superior BA. sustained without trade-off supports role option (Intracoronary Stenting Angiographic Results: Drug Eluting Stent In-Stent Restenosis: Treatment Approaches [ISAR-DESIRE 3]; NCT00987324)
elsevier.com
onlinejacc.org 参考文章(23)
Fernando Alfonso, Maria J. Pérez-Vizcayno, Jaime Dutary, Javier Zueco, Angel Cequier, Arturo García-Touchard, Vicens Martí, Iñigo Lozano, Juan Angel, José M. Hernández, José R. López-Mínguez, Rafael Melgares, Raúl Moreno, Bernhard Seidelberger, Cristina Fernández, Rosana Hernandez, Implantation of a Drug-Eluting Stent With a Different Drug (Switch Strategy) in Patients With Drug-Eluting Stent Restenosis JACC: Cardiovascular Interventions. ,vol. 5, pp. 728- 737 ,(2012) , 10.1016/J.JCIN.2012.03.017
Julinda Mehilli, Robert A Byrne, Klaus Tiroch, Susanne Pinieck, Stefanie Schulz, Sebastian Kufner, Steffen Massberg, Karl-Ludwig Laugwitz, Albert Schömig, Adnan Kastrati, ISAR-DESIRE 2 Investigators, Randomized Trial of Paclitaxel- Versus Sirolimus-Eluting Stents for Treatment of Coronary Restenosis in Sirolimus-Eluting Stents: The ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) Study Journal of the American College of Cardiology. ,vol. 55, pp. 2710- 2716 ,(2010) , 10.1016/J.JACC.2010.02.009
Robert A. Byrne, Salvatore Cassese, Thomas Windisch, Lamin A. King, Michael Joner, Tomohisa Tada, Julinda Mehilli, Jürgen Pache, Adnan Kastrati, Differential relative efficacy between drug-eluting stents in patients with bare metal and drug-eluting stent restenosis; evidence in support of drug resistance: insights from the ISAR-DESIRE and ISAR-DESIRE 2 trials. Eurointervention. ,vol. 9, pp. 797- 802 ,(2013) , 10.4244/EIJV9I7A132
PATRICIA M. GRAMBSCH, TERRY M. THERNEAU, Proportional hazards tests and diagnostics based on weighted residuals Biometrika. ,vol. 81, pp. 515- 526 ,(1994) , 10.1093/BIOMET/81.3.515
Salvatore Cassese, Robert A. Byrne, Stephanie Schulz, Petra Hoppman, Johanna Kreutzer, Antonia Feuchtenberger, Tareq Ibrahim, Ilka Ott, Massimiliano Fusaro, Heribert Schunkert, Karl-Ludwig Laugwitz, Adnan Kastrati, Prognostic role of restenosis in 10 004 patients undergoing routine control angiography after coronary stenting. European Heart Journal. ,vol. 36, pp. 94- 99 ,(2015) , 10.1093/EURHEARTJ/EHU383
Raffaele Piccolo, Gennaro Galasso, Federico Piscione, Giovanni Esposito, Bruno Trimarco, George D. Dangas, Roxana Mehran, Meta-analysis of randomized trials comparing the effectiveness of different strategies for the treatment of drug-eluting stent restenosis American Journal of Cardiology. ,vol. 114, pp. 1339- 1346 ,(2014) , 10.1016/J.AMJCARD.2014.07.069
Yelin Zhao, Bo Xu, Junbo Ge, Yuejin Yang, Jian'an Wang, Shao Liang Chen, Bin Liu, Fang Chen, Run-Lin Gao, TCT-267 Lower Mortality of Paclitaxel-Coated Balloon Compared with Paclitaxel-Eluting Stent for the Treatment of DES In-Stent Restenosis: Two-Year Follow-Up of the PEPCAD China ISR Trial Journal of the American College of Cardiology. ,vol. 64, pp. B78- ,(2014) , 10.1016/J.JACC.2014.07.311
Sebastian Kufner, Robert A. Byrne, Antoinette de Waha, Stefanie Schulz, Michael Joner, Karl-Ludwig Laugwitz, Adnan Kastrati, Sirolimus-eluting versus paclitaxel-eluting stents in diabetic and non-diabetic patients within sirolimus-eluting stent restenosis: results from the ISAR-DESIRE 2 trial. Cardiovascular Revascularization Medicine. ,vol. 15, pp. 69- 75 ,(2014) , 10.1016/J.CARREV.2014.02.001
Fernando Alfonso, Robert A. Byrne, Fernando Rivero, Adnan Kastrati, Current Treatment of In-Stent Restenosis Journal of the American College of Cardiology. ,vol. 63, pp. 2659- 2673 ,(2014) , 10.1016/J.JACC.2014.02.545
Bruno Scheller, Yvonne P. Clever, Bettina Kelsch, Christoph Hehrlein, Wolfgang Bocksch, Wolfgang Rutsch, Dariush Haghi, Ulrich Dietz, Ulrich Speck, Michael Böhm, Bodo Cremers, Long-Term Follow-Up After Treatment of Coronary In-Stent Restenosis With a Paclitaxel-Coated Balloon Catheter JACC: Cardiovascular Interventions. ,vol. 5, pp. 323- 330 ,(2012) , 10.1016/J.JCIN.2012.01.008